The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the
treatment of acid-related gastrointestinal diseases such as reflux esophagitis, duodenal and …

This review summarizes the results of pharmacokinetic and pharmacodynamic drug
interaction studies in man with pantoprazole, a new, selective proton pump inhibitor. Various …

Cultured human hepatocytes are a valuable in vitro system for evaluating new molecular
entities as inducers of cytochrome P450 (P450) enzymes. The present study summarizes data …

Inhaled glucocorticoids induce therapeutic and adverse systemic effects via the same types
of receptors. Analysis of the pharmacokinetic/pharmacodynamic parameters of inhaled …

Background The major drug‐metabolizing enzyme cytochrome P450 (CYP) 3A4 is genetically
conserved. One outlier of Brazilian descent was found in a clinical pharmacokinetic trial …

… nmol/mg protein/min for liver cytosol; the K m1 and K m2 values were 5.4 μM and 910 μM, …
/min and V max2 was 1.09 nmol/mg protein/min, with a K m1 of 9.9 μM and K m2 of 18.7 μM. …

… molar&y of the counter-ion and the column temperature at pH 7.5 and an acetonitrile
concentration of 2.5% on k’ for compounds 1-8 is demonstrated in Tables II-IV. The values in Tables …

Ciclesonide, an inhaled corticosteroid (ICS) with prolonged anti-inflammatory activity, is
being developed for the treatment of asthma. Fatty acid conjugation of ICS is thought to be …

Ciclesonide is a novel glucocorticoid that is converted into ciclesonide—active principle (CIC‐AP)
in the lung. The study objectives were to identify a structural model for population …

Background Ciclesonide is a novel inhaled corticosteroid developed for the treatment of
asthma. Objective To investigate the extent of oral absorption and bioavailability of ciclesonide …